Veru Inc. (VERU)
Last updated: 2026-10-21 16:22:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Veru Inc. (VERU) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.32, with a market capitalization of $39.39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.05 to $7.33. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$39.39M | |
$2.37 | |
$245.70 | |
$2.05 | |
$2.38 | |
40.26K | |
236.35K | |
-- | |
$7.33 | |
$2.05 | |
-- | |
-- |
Veru Inc. (VERU) Stock Price Today
Veru Inc. (VERU) is currently trading at $2.32 as of 2026-10-21 16:20:00, down 2.52% ($0.06) from the previous close of $2.38
During today's regular trading session, VERU has traded between $2.05 and $245.70, with a trading volume of 40.26K shares. The current price is near the lower end of today's range.
Veru Inc. (VERU) 7-Day Stock Price Change
Over the past seven days, Veru Inc. (VERU) moved from $2.41 to $2.32, representing a decline of 3.53% ($0.08).
The stock traded between $2.11 and $2.48 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 217.34 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
VERU 52-Week Price Position
Position in Range: 5.1%
VERU is currently trading at $2.32, placing it 5.1% of the way from its 52-week low of $2.05 to its 52-week high of $7.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Veru Inc. (VERU)?
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Veru Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Veru Inc. (VERU) Stock on MEXC
Eligible investors can buy real shares of Veru Inc. (VERU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Veru Inc. (VERU) stock price today?
2.Is VERU stock going up or down today?
3.What is VERU pre-market price?
4.What is VERU after-hours price?
5.Is VERU stock trading now?
6.Where does VERU sit relative to its 52-week high and low?
7.What sector is Veru Inc. in?
8.What is Veru Inc.'s market capitalization and where is it listed?
9.How is VERU valued in terms of P/E ratio and EPS?
10.Does Veru Inc. pay a dividend?
Explore More US Stocks
Search Stocks
VERU Stock Calculator
Estimate the value between VERU shares and USD.
VERU Shares to USD
1.00 VERU shares = 2.32 USD
Calculations are estimates based on the latest available price and are for reference only.


